FGL2 and neoplasm: However, when we assessed tumour burden at a late timepoint (day 46, immediately prior to the day mice began reaching endpoint) in the orthotopic (i.b.)ID8-p53−/−Brca2−/− model, primary tumour burden was significantly lower in the absence of FGL2 (Fig. 2B).